Four-year entecavir therapy reduces hepatocellular carcinoma, cirrhotic events and mortality in chronic hepatitis B patients

doi:10.1111/liv.13289

科研成果详情

题名	Four-year entecavir therapy reduces hepatocellular carcinoma, cirrhotic events and mortality in chronic hepatitis B patients
作者	Bin-Qiao Wang 1; Yong-Lin Wang 2; Ke-Qing Shi2
发表日期	2017-02-01
发表期刊	Liver international : official journal of the International Association for the Study of the Liver 影响因子和分区
语种	英语
原始文献类型	Letter ; Comment
ISSN	1478-3223
EISSN	1478-3231
卷号	37 期号:2 页码:309-310.
DOI	10.1111/liv.13289
收录类别	PUBMED
URL	查看原文
PubMed ID	27791331
TOP期刊	TOP期刊
引用统计	被引频次：4[WOS] [WOS记录] [WOS相关记录]
文献类型	期刊论文
条目标识符	https://kms.wmu.edu.cn/handle/3ETUA0LF/33762
专题	附属第一医院_妇科附属第一医院
作者单位	1.Department of Gynecology, The First Affiliated Hospital, Wenzhou Medical University, Wenzhou, Zhejiang, China.; 2.Department of Infectious Diseases, The First Affiliated Hospital, Wenzhou Medical University, Wenzhou, Zhejiang, China.
第一作者单位	附属第一医院_妇科
第一作者的第一单位	附属第一医院_妇科
推荐引用方式 GB/T 7714	Bin-Qiao Wang,Yong-Lin Wang,Ke-Qing Shi. Four-year entecavir therapy reduces hepatocellular carcinoma, cirrhotic events and mortality in chronic hepatitis B patients[J]. Liver international : official journal of the International Association for the Study of the Liver,2017,37(2):309-310..
APA	Bin-Qiao Wang, Yong-Lin Wang, & Ke-Qing Shi. (2017). Four-year entecavir therapy reduces hepatocellular carcinoma, cirrhotic events and mortality in chronic hepatitis B patients. Liver international : official journal of the International Association for the Study of the Liver, 37(2), 309-310..
MLA	Bin-Qiao Wang,et al."Four-year entecavir therapy reduces hepatocellular carcinoma, cirrhotic events and mortality in chronic hepatitis B patients".Liver international : official journal of the International Association for the Study of the Liver 37.2(2017):309-310..